Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients-Reference-Cited by-全球学者库

Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients

Published:2017-11-21 Issue:5 Volume:45 Page:735-750
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Lv Zhilei,Fan Jinshuo,Xu Juanjuan,Wu Feng,Huang Qi,Guo Mengfei,Liao Tingting,Liu Shuqing,Lan Xiaoli,Liao Shanshan,Geng Wei,Jin Yang

Funder

National Natural Science Foundation of China

Natural Science Foundation of Hubei Province

Health and Planning Commission Fund of Hubei Province

Science and Technology Support Program of Hubei Province

Wuhan Planning Project of Science and Technology

Independent Innovation Research fund for Huazhong University of Science and Technology

Scientific Training Program for Young Talents from Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Special Fund for Industrial Transformation and Upgrading

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/article/10.1007/s00259-017-3885-z/fulltext.html

Reference67 articles.

1. Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer--recent advances and future perspectives. Int J Cancer. 2016;138:2549–61. https://doi.org/10.1002/ijc.29915 .

2. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57. https://doi.org/10.1056/NEJMoa0810699 .

3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306–11. https://doi.org/10.1073/pnas.0405220101 .

4. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77. https://doi.org/10.1056/NEJMoa1408440 .

5. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94. https://doi.org/10.1056/NEJMoa1214886 .

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Value of multi‐center ¹⁸F‐FDG PET/CT radiomics in predicting EGFR mutation status in lung adenocarcinoma;Medical Physics;2024-01-29

2. Amide Proton Transfer‐Weighted Imaging and Multiple Models Intravoxel Incoherent Motion‐Based ¹⁸F‐FDG PET/MRI for Predicting Progression‐Free Survival in Non‐Small Cell Lung Cancer;Journal of Magnetic Resonance Imaging;2023-10-18

3. The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations;2023-10-04

4. Association between cigarette smoking history, metabolic phenotypes, and EGFR mutation status in patients with non-small cell lung cancer;Journal of Thoracic Disease;2023-10

5. Exploring the correlation between HER2 alterations and 18F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients;Journal of Cancer Research and Clinical Oncology;2023-08-12